Abstract

Type 2 diabetes mellitus’s (DM) patients often receive polypharmacy therapy to prevent complications, but this have potential Drug Related Problems (DRPs). This study aims to determine the profile of the incidence of DRPs in type 2 DM patients, especially in the Outpatient Installation of the Government Type B Hospital in West Nusa Tenggara in 2018. This research was conducted with a cross-sectional design using secondary data with a sampling technique, namely purposive sampling. Respondents involved were type 2 DM patients with complete medical record data and have no comorbid cancer or HIV/AIDS or were pregnant. Thus, the number of respondents involved was 112 patients. The data that has been obtained was then classified into problems and causes of DRPs based on Pharmaceutical Care Network Europe Foundation Version 8.03. The results showed that 80 patients experienced DRPs with a total of 224 DRPs. The pattern of antidiabetic use in the Outpatient Installation of the Government Type B Hospital in NTB in 2018 was dominated by the Biguanide group, namely Metformin (33.85%), followed by Insulin (29.75%), and Sulfonylureas (28.21%). Insulin use was dominated by Insulin Aspart (13.33%), while Sulfonylureas were dominated by Glimepirid (25.13%). DRPs that occurred sequentially were in the category of adverse drug effects that might occur (66.52%), drugs without indications (15.63%), drugs that were not appropriate according to guidelines/formularies (7.14%), symptoms or indications not treated (4 .91%), the frequency of using the dose was insufficient (1.79%), the frequency of using the dose was too frequent (1.79%), the drug dose was too low (1.34%), too many drugs were prescribed for indications (0.45 %), and the drug dose is too high (0.45%). Based on the research, it is known that there are still DRPs in the treatment of type 2 DM patients at the Outpatient Installation of the Government Type B Hospital in NTB where the highest number of events is in the category of adverse drug effects that may occur in patients. Keywords: Antibacteria, Nimba (Azadirachta indica A.Juss), Escherichia coli, Staphylococcus aureus

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call